On May 25, 2021 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, reported that Nima Farzan, Chief Executive Officer of Kinnate, will provide a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually from June 8-11, 2021 (Press release, Kinnate Biopharma, MAY 25, 2021, View Source [SID1234580547]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Goldman Sachs 42nd Annual Global Healthcare Conference
Location: Virtual
Date: Thursday, June 10, 2021
Time: 2:10 PM ET/ 11:10 AM PT

Members of the Kinnate management team will also host investor meetings during the conference.

A live webcast of the Goldman Sachs presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

On May 25, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, reported that it will present at the following virtual conferences in June (Press release, UroGen Pharma, MAY 25, 2021, View Source [SID1234580563]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference

Wednesday, June 2
11:30 AM Eastern Time
Goldman Sachs 42nd Annual Global Healthcare Conference

Wednesday, June 9
8:50 AM Eastern Time
A live webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately 30 days.

On May 25, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery in immuno-oncology, reported the completion of $40 million Series B financing (Press release, Phanes Therapeutics, MAY 25, 2021, View Source [SID1234580579]). The round of financing was led by Sequoia Capital China with participation from new investors and current shareholders. The proceeds from this round will be used to advance several preclinical programs to clinic, expand the research and clinical teams, and support the advancement of research projects in the PACbody and ATACCbody platforms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This round of financing will accelerate our robust growth. We are excited about the opportunity of making a major impact in the immuno-oncology field," said Ming Wang, PhD/MBA, CEO of Phanes Therapeutics, "At Phanes, our mission is to become a major source of innovation in the biopharma industry, and we are fully committed to delivering innovative therapies to patients."

On May 25, 2021 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, reported that the Company will present at the following upcoming investor conferences (Press release, Fate Therapeutics, MAY 25, 2021, View Source [SID1234580627]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:00 p.m. ET
BofA Securities 2021 Napa Biopharma Virtual Conference on Tuesday, June 15, 2021, at 5:30 p.m. ET
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

On May 25, 2021 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021 (Press release, Biodesix, MAY 25, 2021, View Source [SID1234580532]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 41st Annual Growth Stock Conference
Date: Wednesday, June 2, 2021
Time: 2:00 PM CT

The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company’s website at www.biodesix.com.